Zapata Quantum completes oversubscribed $15M financing led by Triatomic Capital

Zapata Quantum, Inc.

$15M oversubscribed round led by Triatomic Capital; other strategic investors participated.
Financing marks final milestone of year-long restructuring; capital to scale platform and team.
Funds to be used to expand science, engineering, product, and commercial functions.
Company highlights quantum-enabled drug discovery research named Nature Biotechnology cover paper in Dec 2025.
Zapata focuses on hardware-agnostic quantum software, closing gap from experimentation to production.

item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.7

Zapata Quantum, Inc. issued common stock to Triatomic Capital and other strategic investors for $15 million.

Security: common stock
Purchaser: Triatomic Capital and other strategic investors
Consideration: $15 million

Exact text from the filing

On April 23, 2026, Zapata Quantum, Inc. (the “Company”) issued a press release announcing the completion of a $15 million financing.

View on SEC.gov

Browse all equity issuances →

Zapata Quantum, Inc. filing history →

Source: SEC EDGAR

accession 0001079973-26-000531

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.